Menu
Search
|

Menu

Close
X

Arena Pharmaceuticals Inc ARNA.OQ (NASDAQ Stock Exchange Global Select Market)

39.97 USD
-0.88 (-2.15%)
As of Feb 23
chart
Previous Close 40.85
Open 40.84
Volume 165,043
3m Avg Volume 184,949
Today’s High 41.00
Today’s Low 38.54
52 Week High 42.72
52 Week Low 11.30
Shares Outstanding (mil) 39.26
Market Capitalization (mil) 1,569.36
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.88 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
21
FY16
124
FY15
38
EPS (USD)
FY17
-2.529
FY16
-0.928
FY15
-4.484
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
14.74
8.35
Price to Book (MRQ)
vs sector
7.18
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
28.66
15.84
LT Debt to Equity (MRQ)
vs sector
26.85
12.39
Return on Investment (TTM)
vs sector
-18.88
13.63
Return on Equity (TTM)
vs sector
-35.27
15.39

EXECUTIVE LEADERSHIP

Tina Nova
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Amit Munshi
President, Chief Executive Officer, Director, Since 2016
Salary: $397,836.00
Bonus: $230,171.00
Kevin Lind
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $218,205.00
Bonus: $96,438.00
Steven Spector
Executive Vice President, General Counsel, Secretary, Since 2012
Salary: $431,600.00
Bonus: --
Vincent Aurentz
Executive Vice President and Chief Business Officer, Since 2016
Salary: $151,538.00
Bonus: $67,025.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

6154 Nancy Ridge Dr
SAN DIEGO   CA   92121-3223

Phone: +1858.4537200

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

SPONSORED STORIES